# US 2017/0283886 A1 · Methods for Diagnosis, Prognosis and Monitoring of Breast Cancer and Reagents Therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283886 A1
- Document ID: US20170283886A1
- Status: Published application
- Kind: A1
- Application number: 15/510,956
- Filed: 2015-09-15
- Published: 2017-10-05
- Earliest claimed: 2014-09-15
- Assignees: Garvan Institute of Medical Research
- Applicants: Garvan Institute of Medical Research
- Inventors: Susan Clark; Elena Zotenko; Clare Stizaker; Glenn Francis
- Web page: https://patentgrep.com/patent/US20170283886A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/154: Methylation markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present disclosure provides methods and reagents for the diagnosis, prognosis or the monitoring of breast cancer, including various subtypes of breast cancer including, for example, estrogen receptor (ER) negative breast cancer, ER positive breast cancer, triple negative breast cancer (TNBC) and other subtypes of breast cancer.

## Claims

### Claim 1

A method for the diagnosis of breast cancer in a subject, said method comprising:
(i) determining the methylation status of one or more CpG dinucleotide sequences within one or more genomic regions defined in Table 1 in a test sample obtained from the subject; and
(ii) identifying differential methylation of said one or more CpG dinucleotide sequences in the test sample relative to a reference level of methylation for the corresponding one or more CpG dinucleotide sequences,
wherein differential methylation of said one or more CpG dinucleotide sequences in the test sample relative to the reference level is indicative of the subject having breast cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein;
(i) increased methylation at one or more CpG dinucleotide sequences within one or more genomic regions defined in Table 1 relative to the reference level is indicative of a subject having breast cancer; and/or
(ii) decreased methylation at one or more CpG dinucleotide sequences within one or more genomic regions defined in Table 1 relative to the reference level is indicative of a subject having breast cancer.

### Claim 3 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the identification of differential methylation of one or more CpG dinucleotide sequences within one or more genomic regions defined in Table 1 relative to the reference level is indicative of a subject having breast cancer which is characterised as being estrogen receptor negative (ER−ve breast cancer.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1 to 3, wherein the identification of differential methylation at one or more CpG dinucleotide sequences within one or more genomic regions defined in Table 2 relative to the reference level of methylation is indicative of the subject having Triple Negative Breast Cancer (TNBC).

### Claim 5

A method for prognosis of, predicting the therapeutic outcome of and/or monitoring the progression of, Triple Negative Breast Cancer (TNBC) in a subject, said method comprising:
(i) determining differential methylation of one or more CpG dinucleotide sequences within one or more genomic regions defined in Table 3 in the subject relative to a reference level of methylation for the corresponding one or more CpG dinucleotide sequences; and
(ii) correlating the differential methylation determined at (i) with a prognosis of the TNBC in the subject.

### Claim 6 (depends on 5)

The method of claim 5, wherein differential methylation of one or more CpG dinucleotide sequences within the one or more genomic regions set forth in Table 3 relative to the reference level is associated with a likelihood of survival of the subject.

### Claim 7 (depends on 6)

The method of claim 6, wherein differential methylation of one or more CpG dinucleotide sequences within any one or more genomic regions defined in rows 1-14 of Table 3 relative to the reference level of methylation is associated with a decreased likelihood of survival of the subject.

### Claim 8 (depends on 6)

The method of claim 6, wherein differential methylation of one or more CpG dinucleotide sequences within any one or more genomic regions defined in rows 15-17 of Table 3 relative to the reference level of methylation is associated with an increased likelihood of survival of the subject.

### Claim 9 (depends on 8)

The method of claim 8, wherein differential methylation of one or more CpG dinucleotide sequences within any one or more genomic regions defined in rows 1-14 of Table 3 relative to the reference level of methylation is associated with a decreased likelihood of survival of the subject and wherein differential methylation of one or more CpG dinucleotide sequences within any one or more genomic regions defined in rows 15-17 of Table 3 relative to the reference level of methylation is associated with an increased likelihood of survival of the subject.

### Claim 10 (depends on 5, 6, 7, 8, 9)

The method of any one of claims 5 to 9, wherein the differential methylation is increased methylation relative to the reference level of methylation.

### Claim 11 (depends on 5, 6, 7, 8, 9, 10)

The method of any one of claims 5 to 10, wherein differential methylation of one or more CpG dinucleotides sequence within the Wilms tumour protein (WT1) gene and/or its antisense counterpart, WT1-AS, is associated with a likelihood of survival of the subject.

### Claim 12 (depends on 11)

The method of claim 11, wherein increased methylation of one or more CpG dinucleotide sequences within the chr11-11623 and/or chr11-1210 genomic regions relative to a reference level of methylation of one or more CpG dinucleotide sequences within those genomic regions is associated with a decreased likelihood of survival of the subject.

### Claim 13 (depends on 11)

The method of claim 11, wherein increased methylation of one or more CpG dinucleotide sequences within the chr11-4047 genomic region relative to a reference level of methylation of one or more CpG dinucleotide sequences within that genomic region is associated with an increased likelihood of survival of the subject.

### Claim 14 (depends on 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 5 to 13, wherein the likelihood of survival is a likelihood that the subject will survive at least 3 years after being diagnosed with TNBC.

### Claim 15 (depends on 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 5 to 14, wherein the likelihood of survival s a likelihood that the subject will survive at least 5 years after being diagnosed with TNBC.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method according to any one of claims 1 to 15, wherein methylation status of one or more CpG dinucleotide sequences within the one or more genomic regions is determined by one or more techniques selected from the group consisting of a nucleic acid amplification, polymerase chain reaction (PCR), methylation specific PCR, bisulfite pyrosequencing, single-strand conformation polymorphism (SSCP) analysis, restriction analysis, microarray technology, and proteomics.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method according to any one of claims 1 to 16, wherein methylation status of one or more CpG dinucleotide sequences within the one or more genomic regions in the test sample is determined by one or more of the following:
(i) performing methylation-sensitive endonuclease digestion of DNA from the subject;
(ii) treating nucleic acid from the subject with an amount of a compound that selectively mutates non-methylated cytosine residues in nucleic acid under conditions sufficient to induce mutagenesis thereof and produce a mutant nucleic acid and amplifying the mutant nucleic acid using at least one primer that selectively hybridizes to the mutant nucleic acid;
(iii) treating nucleic acid from the subject with an amount of a compound that selectively mutates non-methylated cytosine residues in nucleic acid under conditions sufficient to induce mutagenesis thereof and produce a mutant nucleic acid, hybridizing a nucleic acid probe or primer capable of specifically hybridizing to the mutant nucleic acid and detecting the hybridized probe or primer;
(iv) treating nucleic acid from the subject with an amount of a compound that selectively mutates non-methylated cytosine residues in nucleic acid under conditions sufficient to induce mutagenesis thereof and produce a mutant nucleic acid, amplifying the mutant nucleic acid with promoter-tagged primers, transcribing the mutant nucleic acid in vitro to produce a transcript, subjecting the transcript to an enzymatic base-specific cleavage, and determining differences in mass and/or size of any cleaved fragments resulting from mutated cysteine residues, such as by MALDI-TOF mass spectrometry; and
(v) treating nucleic acid from the subject with an amount of a compound that selectively mutates non-methylated cytosine residues in nucleic acid under conditions sufficient to induce mutagenesis thereof, thereby producing a mutant nucleic acid, and determining the nucleotide sequence of the mutant nucleic acid.

### Claim 18 (depends on 17)

The method of claim 17, wherein the compound that selectively mutates non-methylated cytosine residues is a salt of bisulphite.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1 to 18, wherein the methylation status of one or more CpG dinucleotides sequence within the one or more genomic regions is determined in a test sample from the subject comprising tissue and/or a body fluid comprising, or suspected of comprising, a breast cancer cell or components of a breast cancer cell.

### Claim 20 (depends on 19)

The method of claim 19, wherein the sample comprises tissue, a cell and/or an extract thereof taken from a breast or lymph node.

### Claim 21 (depends on 19)

The method of claim 19, wherein the body fluid is selected from the group consisting of whole blood, a fraction of blood such as blood serum or plasma, urine, saliva, breast milk, pleural fluid, sweat, tears and mixtures thereof.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 1 to 21, wherein the reference level of methylation is a level of methylation determined for one or more CpG dinucleotide sequences within a corresponding genomic region of a sample selected from the group consisting of:
(i) a sample from a normal or healthy tissue;
(ii) a sample comprising a non-cancerous cell;
(iii) a sample comprising a cancerous cell other than a TNBC cell;
(iv) an extract of any one of (i) to (iii);
(v) a data set comprising levels of methylation for the one or more CpG dinucleotide sequences within the corresponding genomic region in a normal or healthy individual or a population of normal or healthy individuals;
(vi) a data set comprising levels of methylation for the one or more CpG dinucleotide sequences within the corresponding genomic region in an individual or a population of individuals having cancer of a non-TNBC subtype; and
(vii) a data set comprising levels of methylation for the one or more CpG dinucleotide sequences within the corresponding genomic region in the subject being tested wherein the levels of methylation are determined for a matched sample having normal cells.

### Claim 23

A kit for diagnosing breast cancer in a subject, said kit comprising:
(i) one or more reagents to determine the methylation status of one or more CpG dinucleotide sequences within one or more genomic regions defined in Table 1 in a test sample obtained from the subject; and
(ii) a reference material which provides a reference level of methylation of the corresponding one or more CpG dinucleotide sequences.

### Claim 24

A kit for diagnosing estrogen receptor negative (ER−ve) breast cancer in a subject, said kit comprising:
(i) one or more reagents to determine methylation status of one or more CpG dinucleotide sequences within one or more genomic regions defined in Table 1 in a test sample obtained from the subject; and
(ii) a reference material which provides a reference level of methylation of the corresponding one or more CpG dinucleotide sequences.

### Claim 25

A kit for diagnosing Triple Negative Breast Cancer (TNBC) in a subject, said kit comprising:
(i) one or more reagents to determine methylation status of one or more CpG dinucleotide sequences within one or more genomic regions defined in Table 2 in a test sample obtained from the subject; and
(ii) a reference material which provides a reference level of methylation of the corresponding one or more CpG dinucleotide sequences.

### Claim 26

A kit for prognosis of, predicting the therapeutic outcome of, and/or monitoring the progression of, Triple Negative Breast Cancer (TNBC) in a subject; said kit comprising:
(i) one or more reagents to determine methylation status of one or more CpG dinucleotide sequences within one or more genomic regions defined in Table 2 in a test sample obtained from the subject; and
(ii) a reference material which provides a reference level of methylation of the corresponding one or more CpG dinucleotide sequences.

### Claim 27 (depends on 23, 24, 25, 26)

The kit according to any one of claims 23 to 26, wherein the reference level of methylation is a level of methylation determined for one or more CpG dinucleotide sequences within a corresponding genomic region of a sample selected from the group consisting of:
(i) a sample from a normal or healthy tissue;
(ii) a sample comprising a non-cancerous cell;
(iii) a sample comprising a cancerous cell other than a TNBC cell;
(iv) an extract of any one of (i) to (iii);
(v) a data set comprising levels of methylation for the one or more CpG dinucleotide sequences within the corresponding genomic region in a normal or healthy individual or a population of normal or healthy individuals;
(vi) a data set comprising levels of methylation for the one or more CpG dinucleotide sequences within the corresponding genomic region in an individual or a population of individuals having cancer of a non-TNBC type; and
(vii) a data set comprising levels of methylation for the one or more CpG dinucleotide sequences within the corresponding genomic region in the subject being tested wherein the levels of methylation are determined for a matched sample having normal cells.

### Claim 28 (depends on 1, 2, 16, 17, 18, 19, 20, 21, 22, 23, 27)

The kit according to claim 23 or claim 27, when used in the method of any one of claims 1, 2 or 16 to 22.

### Claim 29 (depends on 3, 16, 17, 18, 19, 20, 21, 22, 24, 27)

The kit according to claim 24 or claim 27, when used in the method of any one of claims 3 or 16 to 22.

### Claim 30 (depends on 4, 16, 17, 18, 19, 20, 21, 22, 25, 27)

The kit according to claim 25 or claim 27, when used in the method of any one of claims 4 or 16 to 22.

### Claim 31 (depends on 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 26, 27)

The kit of claim 26 or claim 27, when used in the method of any one of claims 5 to 22.

### Claim 32

Use of one or more reagents in the preparation of a medicament for diagnosing breast cancer in a subject, wherein the one or more reagents is/are configured to determine methylation status of one or more CpG dinucleotide sequences within one or more genomic regions defined in Table 1 in a test sample obtained from the subject.

### Claim 33

Use of one or more reagents in the preparation of a medicament for diagnosing estrogen receptor negative (ER−ve) breast cancer in a subject, wherein the one or more reagents is/are configured to determine methylation status of one or more CpG dinucleotide sequences within one or more genomic regions defined in Table 1 in a test sample obtained from the subject.

### Claim 34

Use of one or more reagents in the preparation of a medicament for diagnosing Triple Negative Breast Cancer (TNBC) in a subject suspected of having TNBC, wherein the one or more reagents is/are configured to determine methylation status of one or more CpG dinucleotide sequences within one or more genomic regions defined in Table 2 in a test sample obtained from the subject.

### Claim 35

Use of one or more reagents in the preparation of a medicament for prognosis of, predicting the therapeutic outcome of, and/or monitoring the progression of, Triple Negative Breast Cancer (TNBC) in a subject, wherein the one or more reagents is/are configured to determine methylation status of one or more CpG dinucleotide sequences within one or more genomic regions defined in 2 in a test sample obtained from the subject.
